Two co-CEOs just bought $100M of their own stock. - 6/21

Wall Street Sells Words. Insiders Buy With Cash. Here's What They Just Bought.                  

A quick note from Behind the Markets

Wall Street sells words.

Insiders buy with cash.

That's why it pays to watch Form 4 filings like a hawk.

Not because insiders are always right — they're not.

But because size and timing matter. And right now, we're seeing purchases that look like conviction.

1) The loudest signal in the market is insiders putting real money to work

When you see an executive buy a token amount, ignore it.

When you see big purchases clustered together, pay attention.

OpenInsider's weekly list shows several notable buys, including large purchases at Summit Therapeutics (SMMT) by two co-CEOs and a sizable buy at Knot Offshore Partners (KNOP).

The examples that jump off the page:

• Summit Therapeutics (SMMT): Co-CEO Robert W. Duggan bought 3,810,000 shares at $13.12 — about $49,987,200.

• Summit Therapeutics (SMMT): Co-CEO Mahkam Zanganeh bought 3,810,000 shares at $13.12 — another $49,987,200.

• Knot Offshore Partners (KNOP): Director Trygve Seglem bought 1,250,000 shares at $20.00 — about $25,000,000.

This isn't a blind endorsement. But this kind of behavior is good information.

And the Summit buy is a textbook example of why timing matters.

Company: Summit Therapeutics (SMMT)
Clinical-stage biopharma; lead asset ivonescimab, a bispecific antibody for lung and colorectal cancer

Here's the context that makes those two $50 million buys interesting. On June 10, Summit withdrew a planned $500 million stock offering, citing market conditions. Two days later, both co-CEOs stepped in and bought nearly $50 million each in the open market at $13.12 — right after a roughly 10% pullback to around $13. When management cancels a dilutive raise and then buys with their own money instead, that's about as clear a "we think this is cheap" signal as you'll find.

The setup has real catalysts behind it: Summit's HARMONi-6 Phase III trial showed ivonescimab cut the risk of death by 34% versus a competing drug in squamous lung cancer, and it posted strong colorectal data at ASCO. The balance sheet is survivable — roughly $238 million in cash against minimal debt.

SMMT currently trades around $14, well off its 52-week high near $31. Now the hard truth: this is a single-asset, pre-revenue biotech, and the analyst community is genuinely split — consensus targets cluster near $28, but Bernstein initiated at Underperform with a $7.70 target. This is binary. If ivonescimab's global trials disappoint, the downside is severe. The insider buy tells you management has conviction. It does not tell you the science will work. Treat it as a watchlist trigger, not a green light.

Bottom line: Analysts talk. Insiders act. Big insider buys are one of the few signals retail investors can see in real time that isn't filtered through Wall Street.

2) How to use insider buying without getting played

Here's the trap: retail sees insider buying and chases the stock the next day. That's how you become exit liquidity.

A better process. First, confirm it's open-market buying — not options exercises, not grants, not automatic 10b5-1 plans. (On OpenInsider, that's a "P" in the transaction column.) Second, look for clusters — multiple insiders buying around the same time. Third, check the context: is the business hated, is a catalyst coming, is the balance sheet survivable? Fourth, use it as a watchlist trigger, not a "buy now" button.

Let's run a real one through that filter.

Company: Fortune Brands Innovations (SYM: FBIN)
Home, water, and security products — Moen faucets, Master Lock, Yale, SentrySafe

Run the checklist. Open-market? Yes — director Edward Garden bought 320,067 shares at $40.60, about $13 million, a clean "P" purchase. Cluster/conviction? Garden is the co-founder of activist firm Trian Partners, so this isn't a passive board member nibbling — it's an activist adding $13 million. Is the business hated? Absolutely: FBIN is down hard, with the stock near $41 against a 52-week high of nearly $65, beaten up on housing weakness, soft remodel demand, and a string of analyst target cuts. Survivable balance sheet? Yes — this is a profitable, cash-generative maker of everyday home products (it earned roughly $300 million in 2025), not a cash-burner praying for a refinancing.

FBIN currently trades around $41 with a dividend yield near 2.4% and an average analyst target in the mid-$40s. The honest caveat: "hated for a reason" is real — if housing and remodel demand stay soft, the earnings pressure continues, and an activist buying doesn't guarantee a turnaround. But this is exactly the kind of name the checklist surfaces: open-market, sizable, hated, and survivable. That's a watchlist candidate worth real homework.

Bottom line: Insider buying is a filter, not a thesis. It tells you where to do deeper work.

3) The contrarian setup: the best buys happen when headlines feel unsafe

Most insider buying doesn't happen at euphoric tops. It tends to show up when the stock is down, the narrative is broken, and management thinks the market is mispricing the future.

That's exactly when retail investors should be doing their best work. And it's exactly when Wall Street tells you to "wait for clarity."

Clarity is expensive. Uncertainty is where you get paid.

Look back at the two examples through that lens. Summit's co-CEOs didn't buy at the highs near $31 — they bought at $13, after a failed raise and a 10% drop, when the headlines felt unsafe. Trian's Garden didn't add to Fortune Brands when housing was booming — he bought near multi-year lows, with analysts cutting targets and the narrative firmly "avoid."

That's the pattern. The buys that matter most rarely come with a comfortable story attached. By the time the "all-clear" arrives on TV, the insider has already bought, and the discount is gone.

Here's how to put it to work without getting burned. Build a watchlist from clustered, open-market, sizable buys at beaten-down names. Then do the boring work the insiders presumably already did: read the filings, stress-test the balance sheet, identify the catalyst, and size any position for the real possibility you're wrong. Insider conviction narrows the search. It doesn't replace your judgment — and in single-catalyst names like a clinical biotech, "wrong" can mean a permanent loss, not a dip.

Bottom line: If you want to buy great businesses at good prices, you can't wait for the all-clear. Insiders often buy when the all-clear will never come — at least not on TV.

Before You Go

Wall Street has an information edge.

But you have one advantage: you can follow signals that don't require permission.

Form 4 filings are public.